Decreased serum endogenous secretory receptor for advanced glycation endproducts and increased cleaved receptor for advanced glycation endproducts levels in patients with atrial fibrillation

摘要

This clinical protocol was approved by the institutional Medical Ethics Committee and conducted according to the ethical guidelines outlined in the Declaration of Helsinki. A total of 72 consecutive atrial fibrillation (AF) patients who understood this experiment and agreed to participate in this study were enrolled. Another 30 age- and sex-matched healthy people who understood this experiment and agreed to participate in this study were considered as control group. Detailed medical history, physical examination, routine biochemical testing, and 12-lead electrocardiograms were performed both in AF patients and control group. Valvular functions, left ventricular size (left ventricular end-diastolic dimension, LVEDD) and functions (left ventricular ejection fraction, LVEF), and left atrial diameter (LAD) were evaluated by echocardiography. The diameter of the left atrium was measured in parasternal long axis view. AF duration was determined by the patient's description of a well-defined and abrupt onset palpitation with subsequent electrocardiogram evidence of AF at the time of presentation. Exclusion criteria were as follows: structural heart disease, coronary artery disease, left ventricular ejection fraction less than 45%, other types arrhythmias, surgery or stroke within 6 months, a history of infection, chronic inflammatory, hepatic or malign disease, chronic renal failure, autoimmune diseases, abnormal thyroid function, imbalance of electrolytes, use of anti-inflammatory drugs such as corticoids, and nonsteroidal anti-inflammatory drugs excluding aspirin.